Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Nverify (what is YN ?)
Infobox references
Chemical compound
Torcetrapib (CP-529,414, Pfizer) was a drug being developed to treat hypercholesterolemia (elevated cholesterol levels) and prevent cardiovascular disease. Its development was halted in 2006 when phase III studies showed excessive all-cause mortality in the treatment group receiving a combination of atorvastatin (Lipitor) and torcetrapib.
Torcetrapib (CP-529,414, Pfizer) was a drug being developed to treat hypercholesterolemia (elevated cholesterol levels) and prevent cardiovascular disease...
a combination of torcetrapib and atorvastatin, an increase in cardiovascular events and mortality. A compound related to torcetrapib, Dalcetrapib (investigative...
in deaths (torcetrapib), or having no meaningful clinical improvement despite HDL increases (dalcetrapib, evacetrapib). Failed: Torcetrapib, failed in...
increasing HDL by any means is not necessarily helpful. For example, the drug torcetrapib is the most effective agent currently known for raising HDL (by up to...
replacing Henry McKinnell. On December 3, 2006, Pfizer ceased development of torcetrapib, a drug that increases production of HDL, which reduces LDL thought to...
Cholesteryl ester transfer protein (CETP) inhibitors include the agents torcetrapib, anacetrapib and obicetrapib. They block transfer of cholesterol from...
modifies the risk of cardiovascular disease. The first CETP inhibitor, torcetrapib, was unsuccessful because it increased levels of the hormone aldosterone...
cardiovascular risk score for early detection of the harmful effects of Torcetrapib. In 2016 they also developed a test to diagnose latent tuberculosis,...
previous acute coronary events. Other CETP inhibitors:[citation needed] Torcetrapib was developed by Pfizer until December 2006 but caused unacceptable increases...
started and there was no evidence of the raised blood pressure seen with torcetrapib. dal-VESSEL phase IIb trial found no evidence of flow-mediated dilatation...
four of nine points on the graph came from data cited in the paper. Torcetrapib was originally hyped as a drug that could block a protein that converts...
Global Information
verify (what is 
?)
